Cerus Signs INTERCEPT Platelet Agreements With Two Key Blood Component
Suppliers in Germany and Austria
*TILAK, University Clinics, Regional Hospital Innsbruck (LKI), one of the
largest hospitals in Austria, signs one year agreement for Cerus'
INTERCEPT platelet system.
*ZIT GmbH Hamburg (Zentralinstitut Hamburg), the largest in-house blood
component supplier of the German Asklepios Group, signs four year
agreement for the INTERCEPT Blood System for pathogen inactivation of
CONCORD, Calif. -- March 15, 2013
Cerus Corporation (NASDAQ:CERS) announced today that the TILAK, University
Clinics, Regional Hospital Innsbruck (LKI) in Austria and ZIT GmbH Hamburg in
Germany, signed one and four year purchase agreements, respectively, for the
INTERCEPT Blood System for platelets.
LKI is one of the largest hospitals in Austria, with its Central Institute for
Blood Transfusion supplying an estimated 6,000 platelet units annually to the
federal state of Tyrol. LKI is the second facility in Austria to adopt
INTERCEPT for platelets. Together with the General Hospital of Vienna (AKH),
an estimated total of 12,000 platelet units, or 30% of the Austrian platelet
market, could be treated with INTERCEPT. Implementation of the INTERCEPT
platelet system at LKI is expected to start in March 2013.
ZIT Hamburg supplies roughly 10,000 platelet units annually and is the largest
in-house blood component supplier to the Asklepios Group, one of the three
largest operators of private hospitals in Germany. Implementation is expected
to occur upon ZIT Hamburg’s receipt of regulatory approval from the
Paul-Ehrlich-Institut to produce INTERCEPT-treated platelets.
“Considering the inherent limitations and increasing cost of the current
testing strategies used for platelets,we believe the INTERCEPT Blood System
for platelets offers a strong value proposition that combines patient safety
with commercial benefits,” stated O. Schertges, CEO of the ZIT Hamburg.
“We believe the breadth of clinical and routine-use data for INTERCEPT
platelets accumulated over the last 10 years may have positively influenced
the decisions made by LKI and ZIT Hamburg,” said William ‘Obi’ Greenman,
Cerus’ president and chief executive officer.“It is this clinical experience
and hemovigilance data that led to FDA’s recent agreement to allow Cerus to
proceed with a modular PMA submission for INTERCEPT platelets without the need
to conduct another prospective clinical trial.”
Cerus Corporation is a biomedical products company focused on enhancing blood
safety. The INTERCEPT system is designed to reduce the risk of
transfusion-transmitted diseases by inactivating a broad range of pathogens
such as viruses, bacteria and parasites that may be present in donated blood.
The nucleic acid targeting mechanism of action enables INTERCEPT treatment to
inactivate established transfusion threats, such as hepatitis B and C, HIV,
West Nile virus and bacteria, and is designed to inactivate emerging pathogens
such as influenza, malaria and dengue. Cerus currently markets and sells the
INTERCEPT Blood System for both platelets and plasma in Europe, the
Commonwealth of Independent States, the Middle East and selected countries in
other regions around the world. In the United States, Cerus is seeking
regulatory approval of the INTERCEPT Blood System for plasma, and is in the
process of determining the application shell for a potential regulatory
submission for the INTERCEPT Blood System for platelets. The INTERCEPT red
blood cell system is in clinical development. See http://www.cerus.com for
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
Except for the historical statements contained herein, this press release
contains forward-looking statements concerning Cerus’ products, prospects and
results, including statements regarding the expected implementation schedules
of the INTERCEPT platelet system at LKI and ZIT Hamburg. Actual results could
differ materially from these forward-looking statements as a result of certain
factors, including, without limitation, risks associated with demand for the
INTERCEPT Blood System, including the risk that purchases of the platelet
system may be less than anticipated thereunder, risks relating to Cerus’
ability to meet its supply obligations, risks associated with Cerus’ ability
to achieve broader market acceptance of its INTERCEPT Blood System products
and risks associated with obtaining regulatory approvals, as well as other
risks detailed in Cerus’ filings with the Securities and Exchange Commission,
including Cerus’ Quarterly Report on Form 10-Q for the quarter ended September
30, 2012 filed with the SEC on November 8, 2012. Cerus disclaims any
obligation or undertaking to update or revise any forward-looking statements
contained in this press release.
Lainie Corten, 925-288-6319
Senior Director, Global Marketing & Investor Relations
Press spacebar to pause and continue. Press esc to stop.